Pomalidomide - Latest Advances

Risk Evaluation and Mitigation Strategies (REMS) for oral oncolytics: Increased safety or barrier to access?

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 16, 2025

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 08, 2025

Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers.

Journal: Journal of medicinal chemistry

Published: August 01, 2025

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Journal: EJHaem

Published: August 01, 2025

Identification of a Proteolysis-Targeting-Chimera that Addresses Activated Checkpoint Kinase-1 Reveals its Non-Catalytic Functions in Tumor Cells.

Journal: Angewandte Chemie (International ed. in English)

Published: July 07, 2025

Novel therapeutic approaches for multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 06, 2025

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 25, 2025

Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs.

Journal: Expert review of hematology

Published: June 25, 2025

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Journal: Journal of medicinal chemistry

Published: June 18, 2025

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy.

Journal: Frontiers in oncology

Published: June 18, 2025

Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis.

Journal: Clinical hematology international

Published: June 15, 2025

A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation.

Journal: Bioorganic chemistry

Published: June 06, 2025

Filters

Risk Evaluation and Mitigation Strategies (REMS) for oral oncolytics: Increased safety or barrier to access?

Risk Evaluation and Mitigation Strategies (REMS) for oral oncolytics: Increased safety or barrier to access?

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.

Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers.

Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers.

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

Identification of a Proteolysis-Targeting-Chimera that Addresses Activated Checkpoint Kinase-1 Reveals its Non-Catalytic Functions in Tumor Cells.

Identification of a Proteolysis-Targeting-Chimera that Addresses Activated Checkpoint Kinase-1 Reveals its Non-Catalytic Functions in Tumor Cells.

Novel therapeutic approaches for multiple myeloma

Novel therapeutic approaches for multiple myeloma

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.

Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience.

Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs.

Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs.

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy.

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy.

Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis.

Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis.

A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation.

A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation.